Endometriosis

Endometriosis – High-Yield Study Guide for Medical Students

Definition

Endometriosis is defined as the presence of functional endometrial glands and stroma outside the uterine cavity, most commonly on pelvic peritoneal surfaces, ovaries, and rectovaginal septum. These ectopic implants respond to ovarian hormones, leading to cyclic bleeding, chronic inflammation, fibrosis, and adhesions.

Epidemiology

Endometriosis is a common gynecologic condition affecting reproductive-age individuals.

• Prevalence: estimated 6–10% of reproductive-age women, higher (up to 35–50%) in those with chronic pelvic pain or infertility.
• Typical age: usually diagnosed between 25–35 years; rare before menarche and uncommon after menopause unless on exogenous estrogen.
• Risk is increased in patients with first-degree relatives with endometriosis (genetic predisposition).
• Commonly associated with infertility, subfertility, and chronic pelvic pain, making it a major cause of reduced quality of life.

Pathophysiology

The exact pathogenesis is multifactorial and incompletely understood. Several theories likely interact:

• Retrograde menstruation (Sampson theory): Menstrual blood flows through fallopian tubes into the peritoneal cavity, seeding viable endometrial cells on peritoneal surfaces. This is the most widely accepted mechanism.
• Coelomic metaplasia: Peritoneal mesothelial cells undergo metaplasia into endometrial-like tissue under hormonal or inflammatory stimuli.
• Lymphatic/vascular dissemination: Endometrial cells spread hematogenously or via lymphatics, explaining distant sites (e.g., lungs, surgical scars).
• Stem/progenitor cell theory: Bone marrow–derived or endometrial stem cells implant ectopically and differentiate into endometrial tissue.

Once established, lesions involve:

• Estrogen dependence: Lesions are estrogen-responsive, driving proliferation and survival.
• Progesterone resistance: Altered progesterone receptor expression leads to reduced anti-proliferative response to progesterone.
• Inflammatory milieu: Increased peritoneal macrophages, cytokines (e.g., IL-1, TNF-α), prostaglandins, and growth factors sustain chronic inflammation and pain.
• Neuroangiogenesis: Aberrant nerve and blood vessel growth within lesions contributes to pain sensitization and chronic pelvic pain.
• Fibrosis and adhesions: Repeated bleeding and healing lead to scarring and adhesions, distorting pelvic anatomy and impairing fertility.

Clinical Presentation

Symptoms range from asymptomatic to debilitating. Pain severity does not necessarily correlate with disease extent.

• Dysmenorrhea: Classically secondary, progressively worsening menstrual pain, often starting before menses and peaking during menstruation.
• Chronic pelvic pain: Non-cyclic or cyclic pain lasting >6 months, often exacerbated by menses or physical activity.
• Dyspareunia: Especially deep dyspareunia due to involvement of uterosacral ligaments, cul-de-sac, or rectovaginal septum.
• Infertility/subfertility: Endometriosis is present in a significant proportion of infertile women; mechanisms include distorted anatomy, altered peritoneal fluid, impaired ovum pickup, and possible endometrial receptivity defects.
• Dyschezia and painful defecation: Especially with bowel involvement or deep infiltrating endometriosis (DIE) in rectovaginal septum.
• Dysuria, urinary frequency, hematuria: When bladder or ureter is involved.
• Other symptoms: Fatigue, low back pain, and cyclical symptoms at extrapelvic sites (e.g., catamenial chest pain or hemoptysis with thoracic endometriosis).

On exam, findings may include:

• Uterine immobility or fixed retroversion due to adhesions.
• Tenderness in the posterior fornix or uterosacral ligaments.
• Palpable nodules in uterosacral ligaments or rectovaginal septum.
• Adnexal masses consistent with endometriomas ("chocolate cysts").

Common Sites of Endometriosis

• Ovaries (endometriomas)
• Pelvic peritoneum (uterosacral ligaments, cul-de-sac, broad ligaments)
• Rectovaginal septum
• Bladder and ureters
• Abdominal wall and surgical scars (e.g., post-cesarean)
• Less common: diaphragm, pleura, lungs, umbilicus

Diagnosis

Clinical suspicion is key, particularly in patients with chronic pelvic pain, dysmenorrhea unresponsive to NSAIDs/OCPs, or infertility.

History and Physical Examination

• Detailed menstrual and pain history (onset, cyclicity, severity, response to analgesia).
• Reproductive history and infertility evaluation.
• Pelvic exam to assess uterine mobility, adnexal masses, and tenderness/nodularity of uterosacral ligaments.

Imaging

Imaging supports the diagnosis and is especially useful for identifying endometriomas and deep infiltrating disease.

• Transvaginal ultrasonography (TVUS): First-line imaging.
• Endometriomas appear as homogeneous, low-level "ground glass" echogenic cysts.
• TVUS can identify ovarian endometriomas and some deep lesions (e.g., rectovaginal nodules, bladder lesions) with experienced operators.
• MRI: Second-line for mapping deep infiltrating endometriosis or equivocal cases; useful preoperatively to delineate bowel, bladder, and ureter involvement.

Definitive Diagnosis

The gold standard is direct visualization of lesions via laparoscopy with histologic confirmation of endometrial glands and stroma in biopsy specimens.

• Laparoscopy reveals classic lesions: "powder-burn" or "gunpowder" lesions, red flame-like lesions, clear vesicles, white plaques, adhesions, and endometriomas.
• Staging is typically done using systems such as the revised American Society for Reproductive Medicine (rASRM) classification, grading disease from minimal (Stage I) to severe (Stage IV) based on lesions and adhesions. Note: stage correlates poorly with pain but somewhat with infertility risk.

Laboratory Markers

• CA-125 may be elevated, especially with advanced disease or endometriomas, but is nonspecific and not diagnostic.
• No reliable serum biomarker currently replaces the need for clinical assessment and imaging/laparoscopy.

Management

Management is individualized based on symptoms (pain vs infertility), age, desire for future fertility, disease extent, and patient preference. Goals are symptom control, improvement in quality of life, and preservation/optimization of fertility.

General Principles

• Empiric medical therapy is reasonable in patients with typical symptoms, even without surgical confirmation.
• First-line pharmacologic options target ovarian suppression and reduction of estrogen-driven lesion activity.
• Surgery is reserved for refractory pain, endometriomas, anatomical distortion, or infertility when appropriate.

Medical Management of Pain

1. NSAIDs

• Indication: First-line for dysmenorrhea and mild pain.
• Agents: ibuprofen, naproxen, others; used cyclically around menses or continuously for chronic pain.
• Mechanism: Inhibit prostaglandin synthesis, reducing uterine and ectopic lesion prostaglandin-mediated pain.

2. Combined Hormonal Contraceptives (CHCs)

• First-line hormonal therapy for endometriosis-associated pain in patients not seeking conception.
• Available as combined oral pills, patch, or vaginal ring.
• Given cyclically or continuously; continuous regimens reduce menstruation and often provide better pain control.
• Mechanism: Ovarian suppression, decidualization and atrophy of endometrial tissue, decreased menstrual flow and retrograde menstruation.

3. Progestin-Only Therapy

• Options: oral progestins (e.g., norethindrone acetate, dienogest where available), depot medroxyprogesterone acetate (DMPA), levonorgestrel intrauterine system (LNG-IUS).
• Mechanism: Progesterone-dominant environment leads to decidualization and atrophy of ectopic endometrium and suppression of ovulation (most formulations).
• LNG-IUS is particularly useful for patients with predominant dysmenorrhea and pelvic pain who desire long-term reversible contraception.

4. Gonadotropin-Releasing Hormone (GnRH) Agonists and Antagonists

• Used as second-line for moderate-to-severe pain refractory to first-line hormonal therapy.
• GnRH agonists (e.g., leuprolide): cause initial flare then downregulation of pituitary GnRH receptors, leading to hypoestrogenic state ("medical menopause").
• GnRH antagonists (e.g., oral agents such as elagolix where approved): provide more immediate suppression of gonadotropins without flare.
• Adverse effects: vasomotor symptoms, decreased bone mineral density; typically used with "add-back" therapy (low-dose estrogen/progestin) to mitigate hypoestrogenic side effects while maintaining efficacy.

5. Other Hormonal Options

• Danazol (androgenic derivative): historically used; induces hypoestrogenic, hyperandrogenic state. Now less favored due to androgenic side effects (weight gain, acne, hirsutism, adverse lipid profile).
• Aromatase inhibitors (e.g., letrozole, anastrozole): reduce estrogen production including extraovarian production within lesions; usually combined with ovarian suppression (e.g., GnRH analog or progestin) to avoid follicular cyst development. Reserved for refractory cases.

Surgical Management

Surgery is preferred in patients with:

• Severe, refractory pain despite optimal medical therapy.
• Endometriomas >4 cm (especially if symptomatic or impacting IVF access).
• Deep infiltrating endometriosis affecting bowel, bladder, or ureter.
• Infertility associated with suspected mechanical distortion or endometriomas.

Conservative Surgery

• Laparoscopic excision or ablation of visible lesions.
• Adhesiolysis to restore normal pelvic anatomy.
• Cystectomy for endometriomas, ideally via stripping technique; care to preserve ovarian reserve.
• Goal: relieve pain and improve fertility while preserving uterus and ovaries.

Definitive Surgery

• Hysterectomy with bilateral salpingo-oophorectomy (BSO) may be considered for severe, refractory disease in patients who have completed childbearing.
• Even with hysterectomy, complete excision of all visible disease is important; ovarian conservation may increase recurrence risk.

Management of Endometriosis-Associated Infertility

• Mild to moderate disease: Laparoscopic excision/ablation of lesions and adhesiolysis can improve spontaneous pregnancy rates.
• Ovulation induction with intrauterine insemination (IUI) may be used in selected patients with mild disease and adequate tubal patency.
• In vitro fertilization (IVF) is often the most effective option in moderate to severe disease, bilateral endometriomas, advanced age, or concomitant male factor infertility.
• Prolonged postoperative medical suppression (e.g., GnRH agonist therapy) may improve IVF outcomes in some patients by decreasing lesion activity and inflammation.

Key Clinical Pearls and Exam Tips

• Classic triad: dysmenorrhea, dyspareunia, and infertility in a reproductive-age patient.
• Pain severity does not correlate with stage of disease; minimal disease can cause severe pain, and vice versa.
• Consider endometriosis in adolescents and young adults with secondary dysmenorrhea unresponsive to NSAIDs and first-line hormonal therapy.
• Endometrioma on ultrasound: homogenous "ground glass" cyst in the ovary; often termed "chocolate cyst" due to old blood content.
• First-line therapy for pain: NSAIDs plus combined oral contraceptives or progestin-only therapy in patients not currently desiring pregnancy.
• Empiric hormonal therapy is appropriate based on symptoms; laparoscopy is not mandatory for initial management.
• Laparoscopic visualization and biopsy remain the gold standard for definitive diagnosis and staging.
• In patients primarily desiring fertility, avoid long-term suppressive therapy without a reproductive plan; consider early referral to reproductive endocrinology if needed.
• Endometriosis is associated with an increased risk of ovarian epithelial cancers (especially clear cell and endometrioid subtypes), but absolute risk remains low; clinical vigilance is recommended.
• Recurrence after surgery is common, especially without postoperative hormonal suppression; ongoing management often requires a chronic disease approach.

Summary for Exams

Endometriosis is a chronic, estrogen-dependent condition characterized by ectopic endometrial tissue leading to pelvic pain, dysmenorrhea, dyspareunia, and infertility. Diagnosis is suggested clinically and supported by imaging (TVUS for endometriomas), with laparoscopy and histology as the definitive standard. Management is guided by symptom burden and fertility desires, with NSAIDs and hormonal suppression (CHCs or progestins) as first-line therapies, and surgery reserved for refractory pain, significant endometriomas, anatomical distortion, or infertility. Recognizing the classic clinical presentations and first-line treatments is high-yield for exams and clinical practice.